Safety of Purified Poloxamer 188 in Sickle Cell Disease: Phase I Study of a Non‐ionic Surfactant in the Management of Acute Chest Syndrome-Reference-Cited by-同舟云学术

Safety of Purified Poloxamer 188 in Sickle Cell Disease: Phase I Study of a Non‐ionic Surfactant in the Management of Acute Chest Syndrome

Published:2004-01 Issue:2 Volume:28 Page:85-102
ISSN:0363-0269
Container-title:Hemoglobin
language:en
Short-container-title:Hemoglobin

Author:

Ballas Samir K.,Files Beatrice,Luchtman‐Jones Lori,Benjamin Lennette,Swerdlow Paul,Hilliard Lee,Coates Thomas,Abboud Miguel,Wojtowicz‐Praga Slawomir,Grindel J. Michael

Publisher

Informa UK Limited

Subject

Biochemistry (medical),Clinical Biochemistry,Genetics (clinical),Hematology

Link

http://www.tandfonline.com/doi/pdf/10.1081/HEM-120035919

Reference36 articles.

1. Mortality In Sickle Cell Disease -- Life Expectancy and Risk Factors for Early Death

2. Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease

3. Pulmonary fat embolism: a distinct cause of severe acute chest syndrome in sickle cell anemia

4. Acute chest syndrome and sickle cell disease

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Amorphous solid dispersions of triclabendazole: Keeping the supersaturated drug solution using poloxamers;Journal of Drug Delivery Science and Technology;2024-01

2. Discovery of Kinetic Trapping of Poloxamers inside Liposomes via Thermal Treatment;Langmuir;2023-09-27

3. Duchenne muscular dystrophy: disease mechanism and therapeutic strategies;Frontiers in Physiology;2023-06-26

4. Rapid restitution of contractile dysfunction by synthetic copolymers in dystrophin-deficient single live skeletal muscle fibers;Skeletal Muscle;2023-05-19

5. Emerging Therapies for the Management of Pain and Vaso-Occlusive Crises in Patients With Sickle Cell Disease: A Systematic Review of Randomized Controlled Trials;Cureus;2023-04-23